Celebrating 40 Years of Catheter Ablation: The Legacy of Dr. Melvin Scheinman

Photo credit: Marco Sanchez, UCSF

Four decades ago, the medical landscape for patients suffering from cardiac arrhythmias was bleak. The available interventions were limited to medications that often failed or highly invasive open-heart surgeries.

Enter Dr. Melvin Scheinman, the Walter H. Shorenstein Endowed Chair in Cardiology at UCSF. Dr. Scheinman dedicated years to pioneering a non-surgical alternative. In 1981, he achieved a medical milestone by performing the first human catheter ablation. By navigating a catheter through the vasculature and into the heart, he delivered a targeted electrical shock to "short-circuit" the malfunctioning rhythm.

"Scheinman’s contribution to the field has been one of the most transformative in all of electrophysiology," notes Jeffrey Olgin, MD, chief of the UCSF Division of Cardiology.

---

🎓 The Academic Journey

Dr. Scheinman's path to this breakthrough began in 1965 when he joined UCSF as a cardiology fellow. He was attracted by the cutting-edge research at the Cardiovascular Research Institute and the opportunity to mentor under giants in the field:

• Maurice Sokolow, MD: A leading electrocardiographer and chief of the Division of Cardiology.
• Lloyd Hollingsworth “Holly” Smith, Jr., MD: The esteemed chair of the Department of Medicine.

After joining the faculty, Scheinman established the Coronary Care Unit (CCU) at San Francisco General Hospital (SFGH), an experience that sparked his lifelong obsession with heart rhythm disorders. To deepen his expertise, he took a sabbatical in the mid-1970s at Duke University, studying under Harold Strauss, MD, and John Gallagher, MD, where he mastered the art of mapping human heart rhythm disorders.

---

💡 The Conceptual Leap

The inspiration for catheter ablation was derived from existing surgical practices. Surgeons were already destroying the electrical pathways that allowed impulses to travel from the top to the bottom of the heart to treat severe atrial fibrillation. However, many patients were too frail to survive such an invasive operation.

The Evolution of the Approach

---

🛠️ Engineering the Breakthrough

Until Scheinman's work, catheters were purely diagnostic tools used to listen to electrical signals. He needed a tool capable of delivering high-energy currents without failing.

The Experimental Process: Scheinman and his team utilized a "trial and error" approach, which involved a rather low-tech setup:

"We were trying to identify catheters that had high resistivity and could accommodate large surges of current flow without exploding…."

They submerged various catheters in buckets of saline, discharging massive electrical currents through them. Eventually, they discovered a specific catheter manufactured by the company Bard that could withstand the energy requirements.

The Collaborative Team

The success of the project relied on a multidisciplinary effort:

The pathologists confirmed that while the procedure created necessary scarring to block the arrhythmia, it did not damage the $\text{valves}$, $\text{blood vessels}$, or $\text{arteries}$.

---

🏥 The First Human Procedure

Before moving to humans, the team adhered to a strict validation protocol:

• Complete 3 years of preclinical research.
• Perform 10 consecutive successful ablations in animal models.
• Verify pathology results from the Hektoen Institute.

The Patient: Paul Anderson

The first candidate was Paul Anderson, a retired oil field worker. His medical profile was complex:

1. Primary Condition: Atrial Fibrillation (where the upper chambers quiver instead of contracting).
2. Complication: Severe heart failure that resisted drug therapy.
3. Contraindications: Severe chronic obstructive pulmonary disease (COPD) and rheumatoid arthritis.

Because of his comorbidities, surgery was impossible. The electrical chaos in his heart could be represented by a rapid, irregular heart rate: $\text{Heart Rate} \approx \text{Chaotic/Rapid Beats per Minute (BPM)}$

An Ethical Dilemma

Because Dr. Scheinman was so emotionally and professionally invested in the research, he felt he could not objectively present the risks to the patient. He requested that a colleague, David Hess, MD, handle the informed consent process to ensure the patient's decision was unbiased.

# Simulation of the decision process
patient_consent = "Accepted"
preclinical_success = True

if patient_consent == "Accepted" and preclinical_success:
    print("Proceed to procedure on April 9, 1981")
else:
    print("Continue research")

On the morning of April 9, 1981, Dr. Scheinman stepped forward to change the course of cardiac medicine.